ClavystBio, a Temasek-backed life sciences investor and venture builder, has partnered with Singapore’s lead R&D agency, ASTAR, to catalyze MedTech innovation through a two-year strategic collaboration. By integrating ClavystBio’s investment and venture-building expertise with ASTAR’s robust research and productisation platforms—namely MedTech Catapult and DxD Hub—the partnership aims to accelerate the creation of high-potential medical technology ventures. This alignment offers a streamlined pathway from lab-based discoveries to commercially viable medical devices, diagnostics, and digital health solutions.

This collaboration is especially timely as Singapore’s MedTech sector gains momentum, with output reaching S$20 billion in 2023 and regional market projections exceeding US$225 billion by 2030. The partnership focuses on key innovation areas: fostering new ventures from A*STAR’s research pipeline, advancing product development, and enhancing commercial readiness in diagnostics and digital health. With joint efforts to identify promising technologies and co-develop market-ready solutions, the initiative addresses both innovation gaps and commercialisation hurdles in Asia’s growing healthcare ecosystem.

Ultimately, this partnership reinforces Singapore’s ambition to be a global MedTech innovation hub. By combining deep scientific capabilities with strategic capital and venture support, ClavystBio and A*STAR are laying the foundation for a vibrant, innovation-driven ecosystem. The collaboration not only strengthens national competitiveness but also positions Singapore-based startups for global scale—fostering long-term value across healthcare, technology, and the broader life sciences sector.

MedTech Spectrum's Summary

Accelerates MedTech Innovation: The partnership combines A*STAR’s research and productisation strengths with ClavystBio’s venture-building and funding capabilities to fast-track the creation of commercially viable medical technologies.

Strengthens Singapore’s Ecosystem: Focused on diagnostics, digital health, and medical devices, the initiative supports the national goal of positioning Singapore as a leading MedTech hub in Asia.

Enables Global Scale: By bridging scientific innovation with market readiness, the collaboration creates a robust pipeline of globally investible ventures—fueling long-term healthcare impact and economic growth.